Please ensure Javascript is enabled for purposes of website accessibility

Pfizer and BioNTech's Coronavirus Vaccine Remains Effective for at Least 6 Months

By Eric Volkman - Updated Apr 1, 2021 at 9:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Top-line results from clinical trials also show the jab protects against the so-called South African variant.

People who've been inoculated with the BNT162b2 coronavirus vaccine from Pfizer (PFE 1.50%) and BioNTech (BNTX -4.81%) can look forward to its protection lasting for a minimum of six months.

On Thursday, the two companies released a top-line analysis from 927 confirmed cases of COVID-19, the disease triggered by the coronavirus. This indicates that the jab was over 91% effective against the affliction -- an extremely high number for any vaccine. Very encouragingly, this was tracked from one week to six months after the recipients received their second shot of the two-shot BNT162b2.

Child getting a syringe jab from a medical professional.

Image source: Getty Images.

The worse the disease, the better the performance of the vaccine. Pfizer and BioNTech said it was more than 95% effective against severe COVID-19 as defined by the Food and Drug Administration, and 100% effective according to the standards of the Centers for Disease Control and Prevention (CDC).

The shot seems to block the so-called South African variant of the coronavirus, too. The two companies' study indicates that BNT162b2 produced a "robust" neutralizing response to the variant. Many healthcare authorities are worried by the variant, as it appears to be more highly contagious than the original strain of the coronavirus. Many experts have expressed concern that vaccines might not be as effective against it.

Pfizer and BioNTech added that no serious safety concerns were recorded with any participants in the trial, again up to six months after their receiving dose No. 2. The companies said they aim to submit detailed data from the trial for peer review and possible publication. 

Despite the good news, Pfizer stock barely inched up on Thursday, and was trounced by the 1.2% rise of the S&P 500 index. BioNTech, on the other hand, shot 4.3% higher.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.67 (1.50%) $0.75
BioNTech SE Stock Quote
BioNTech SE
BNTX
$151.20 (-4.81%) $-7.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.